Key facts
- It has raised $2.4M; the latest was Equity Crowdfunding ($1.3M) in Sep 2025.
- Notable investors include CS Group, European Institute of Innovation and Technology, Francisco Javier Alsina, Montserrat Esteve, NeuroTechnology Investors.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for FreeOx
- ·The full record, as it builds
Funding rounds
No funding rounds for FreeOx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FreeOx
Developer of cerebrovascular protective therapies designed to reduce the effects of oxidative stress related to the neurological and cardiovascular systems. The company's drug includes a molecule with neuroprotective properties that has a proven effect in preventing the damage caused by reperfusion after stroke, enabling patients to recover without disabilities.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2017
- Employees
- 6
- Website
- freeoxbiotech.com/
- Ownership
- Privately Held (backing)
FreeOx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FreeOx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FreeOx in its N-PORT filings yet. We sweep new filings monthly.